TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03383900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 6 days a week for 8 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 6 days a week for 8 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value.
Study: NCT01585610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Intervention
Description: Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (\< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Printed Materials
Description: Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (\< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
Study: NCT00908076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LUBIPROSTONE
Description: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LUBIPROSTONE
Description: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
Study: NCT00344591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Ecosystems Therapy (SET)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individually tailored intervention
Study: NCT03657940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIVIFRAIL multicomponent exercise training program
Description: The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using dumbbells aiming for 2-3 sets of 10-15 repetitions at an intensity of 30-50% of 1Repetition Maximum ( combined with balance-training, flexibility and gait exercises that progressed in difficulty.
Study: NCT02470819

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic profiling
Description: genetic profiling
Study: NCT01490697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-Cycloserine
Description: 100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Mifepristone
Description: Placebo-matching mifepristone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching d-Cycloserine (DCS)
Description: Placebo-matching DCS capsules
Study: NCT03035734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986141 Form A Tablet
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141 Form B tablet (low dose)
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141 Form B tablet (high dose)
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141 Form B tablet (high dose)
Description: tablet
Study: NCT03756025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART)
Description: The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique \[20\], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Description: The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique \[20\], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
Study: NCT03675295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalase
Description: injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: injection of 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT00782600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suspension IR
Description: 50 mg IR suspension once daily for one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR 1
Description: 50 mg shorter release CR once daily for one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR 2
Description: 50 mg medium release CR once daily for one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR 3
Description: longer release SR formulation once daily for one day
Study: NCT03803228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUOSTIM
Description: 2 consecutive stimulations by Fertistartkit® on the same cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional stimuli
Description: 2 stimulations by Fertistartkit® performed on 2 different cycles
Study: NCT04779606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocular gel
Description: 3 drops instilled in the right eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ocular gel
Description: 3 drops instilled in the right eye
Study: NCT01031745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency
Description: Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prize bowl drawings
Description: Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives.
Study: NCT03051516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study: NCT01688778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks.
Study: NCT05100498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool
Description: The website structure was developed to satisfy the needs of reproductive-age women was investigated based on four domains of social support, as developed by Cohen and Syme (1985). The important needs of patients can be classified as emotional, informational, appraisal, and instrumental support.
Study: NCT03451110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemborexant
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemborexant
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemborexant
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: oral tablet
Study: NCT03156907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
Study: NCT00621465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Description: CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care will include the standard aftercare and community care services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care will include the standard aftercare and community care services.
Study: NCT01675154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-4090 placebo
Description: Given for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SLx-4090 placebo
Description: Given for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat Placebo
Description: Given for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orlistat Placebo
Description: Given for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Given for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Given for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slx-4090
Description: Given for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slx-4090
Description: Given for 4 weeks
Study: NCT01826370

Intervention type: DRUG
Intervention: Linagliptin
Description: tablet
Study: NCT01300208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050
Description: Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050
Description: Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050
Description: Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02165475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stool bulking agent (stericulia or isphagula husk)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of biofeedback and medical treatment
Study: NCT02071810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03873441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Games-Aided Balance Training Protocol
Description: 1) Sitting Balance exercises while playing the interactive computer games starting with bi manual object placed in hands for controlling the games, then using the head rotation movements to control the games progressing to use of trunk motions to control games while balancing on the compliant surfaces in order to progress by increasing the balance costs.~(2) Standing Balance exercises progressing from a fixed support surface to uneven, compliant surfaces like progression from standing over ground to sponge to air bladder as child tolerates increased balance costs.~(3) Progression then to balancing while performing the visuomotor and visuospatial game tasks such as playing the games starting with bi-manual object placed in hands for controlling the games, then using the head rotation movements to control the games and then progressing to use of trunk motions to control games while balancing on compliant surface.~(4) Progression to single-leg stance and stepping activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance Training Protocol
Description: The following is a summary of the conventional physical therapy balance training protocol:~1. Active-assisted stretching exercises for lower limb musculature focusing on postural control and improvement in dynamic stability,~2. Balance and weight bearing exercises with multi-directional reach outs associated with trunk movements on fixed surface gradually progressing to unstable movable and compliant surfaces,~3. Weight transfer exercises with multi-directional reach outs and~4. Stepping exercises in different directions on variety of surfaces.
Study: NCT02675998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00900406

Intervention type: GENETIC
Intervention: gene expression analysis
Description: blood collection

Intervention type: GENETIC
Intervention: gene expression analysis
Description: blood collection

Intervention type: GENETIC
Intervention: gene expression analysis
Description: blood collection

Intervention type: GENETIC
Intervention: microarray analysis
Description: Blood collection

Intervention type: GENETIC
Intervention: microarray analysis
Description: Blood collection

Intervention type: GENETIC
Intervention: microarray analysis
Description: Blood collection

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: Blood collection

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: Blood collection

Intervention type: GENETIC
Intervention: polymorphism analysis
Description: Blood collection

Intervention type: GENETIC
Intervention: proteomic profiling
Description: Blood collection

Intervention type: GENETIC
Intervention: proteomic profiling
Description: Blood collection

Intervention type: GENETIC
Intervention: proteomic profiling
Description: Blood collection
Study: NCT00970099

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non exercise
Description: subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
Study: NCT02777944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivate: a web-based intervention
Description: A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
Study: NCT00900406

Intervention type: OTHER
Intervention: flow cytometry
Description: Blood collection

Intervention type: OTHER
Intervention: flow cytometry
Description: Blood collection

Intervention type: OTHER
Intervention: flow cytometry
Description: Blood collection

Intervention type: OTHER
Intervention: immunologic technique
Description: Blood collection

Intervention type: OTHER
Intervention: immunologic technique
Description: Blood collection

Intervention type: OTHER
Intervention: immunologic technique
Description: Blood collection

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood collection

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood collection

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood collection

Intervention type: PROCEDURE
Intervention: biopsy
Description: Blood collection

Intervention type: PROCEDURE
Intervention: biopsy
Description: Blood collection

Intervention type: PROCEDURE
Intervention: biopsy
Description: Blood collection
Study: NCT04200404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
Study: NCT01194271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 22.5 mg administered as a single intramuscular 3 month depot.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
Study: NCT02246634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted MRI scan
Description: Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
Study: NCT01929577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral tablet
Study: NCT04349657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supera Peripheral Stent System treatment group
Description: Percutaneous endovascular stenting with the Supera Peripheral Stent System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endarterectomy treatment group
Description: Surgical treatment through endarterectomy